title: Evaluation of CYFRA 21-1 as a new marker for non-small cell lung cancer.
abstract: The levels of the new tumour marker CYFRA 21-1 were assessed in 115 patients with non-small cell lung cancer (NSCLC) and in 45 patients with non-malignant lung disease. Increased levels of CYFRA 21-1 were observed in 47.8%, mostly in patients with squamous cell carcinoma (SCC; 69.1%). Serum CYFRA 21-1 levels were correlated with the stage of SCC type. Positive CYFRA 21-1 levels in patients with SCC were present in 40% of stage I, 61.1% of stage II, and 85.2% of stage III. In addition, SCC patients who presented mediastinal lymph nodes (N2) demonstrated higher serum CYFRA 21-1 levels, compared with patients without mediastinal lymph nodes metastases (N0 or N1). With regard to tumour size, significant difference was observed between T1, T2 and T3. The study also showed that the percentage of patients who survived 18 months with normal preoperative level of CYFRA 21-1 was higher compared with those patients with elevated preoperative levels of this marker, but the differences were not statistically significant.
authors.affiliation: Department of Thoracic Surgery, Medical School, Bialystok, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Niklinski
authors.forename: M
authors.initials: M
authors.lastname: Furman
authors.forename: E
authors.initials: E
authors.lastname: Chyczewska
authors.forename: L
authors.initials: L
authors.lastname: Chyczewski
authors.forename: F
authors.initials: F
authors.lastname: Rogowski
authors.forename: E
authors.initials: E
authors.lastname: Jaroszewicz
authors.forename: J
authors.initials: J
authors.lastname: Laudanski
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology / Q000556:secondary; D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D018287:Carcinoma, Large Cell / Q000097:blood / Q000473:pathology / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000473:pathology / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000473:pathology / Q000556:secondary; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007633:Keratins / Q000097:blood*; D008171:Lung Diseases / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D010446:Peptide Fragments / Q000097:blood; D015843:Serpins
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010446:Peptide Fragments; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; D007633:Keratins